axicabtagene ciloleucel

This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.

Gilead optimistic about Yescarta deal in UK

Yescarta (axicabtagene ciloleucel) and its rival CAR-T therapy Novartis’Kymriah (Tisagenlecleucel-T) were granted European approved on the same day in relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Latest news

Novartis’ CAR-T Kymriah gets green light in England

The rapid agreement on Kymriah is in stark contrast to NICE’s speedy rejection in draft guidance of Gilead/Kite Pharma’s rival CAR-T Yescarta (axicabtagene ciloleucel), which was approved
It’s a no for Yescarta, says NICE on heels of EU approval

The appraisal document for Yescarta (axicabtagene ciloleucel ) notes that the therapy “is not recommended, within its anticipated marketing authorisation, for treating relapsed or refractory diffuse large B-cell lymphoma or primary ... While Yescarta
MaxCyte gets green light for solid tumour cell therapy

The current generation of CAR-T therapies – namely Novartis’Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) – use engineered T cells harvested from blood, which have to be expanded in
CAR-Ts Kymriah and Yescarta step closer to approval in Europe

However the EMA has been working on its own fast-track for the most important new drugs, the PRIority MEdicines (PRIME) scheme, and Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) are the
New trial results suggest CAR-T effects are durable in lymphoma

Yescarta (axicabtagene ciloleucel or axi-cel) which was approved for that indication the previous October and made $40m in the first quarter, ahead of the $16m predicted by analysts.

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

The European Medicines Agency: PRIME’d for access?

Early signs are looking good: Novartis’Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
Deal Watch January 2017

Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Associate Director: £75, 000-90, 000

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Consultant Health Economics - London / Oxford: Negotiable

Client Services Director – Medical Education Agency – North West...: Salary TBC

New Business Director - PR: Competitive Salary and benefits

Senior Medical Writer: Competitive Salary

Account Director: £48, 000 - £60, 000

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Medical/ Scientific Director: Salary TBC

Consumer Health Account Director: Circa £60, 000 Gym and More

Medical Writers Required – Cheshire: DOE

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Director - Healthcare Advertising - London - HOME WORKIN...: £50000 - £68000

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Production Manager – Healthcare Communications: DOE

Senior Medical Writer: Great salary and benefits

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Associate Editorial Director – Med Comms – London: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Senior Account Executive, London, Medical Communications: Excellent package

Associate Director, Market Access & HEOR – North-West: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...